...
首页> 外文期刊>Cardiovascular and Interventional Radiology: A Journal of Imaging in Diagnosis and Treatment >Fenestrated Thoracic Endovascular Aortic Repair Using Physician-Modified Stent Grafts (PMSGs) in Zone 0 and Zone 1 for Aortic Arch Diseases
【24h】

Fenestrated Thoracic Endovascular Aortic Repair Using Physician-Modified Stent Grafts (PMSGs) in Zone 0 and Zone 1 for Aortic Arch Diseases

机译:使用医生改性的支架移植(PMSGS)在0和1区的主动脉弓疾病中使用医生改性支架移植物(PMSG)进行了近期胸腔血管内的主动脉修复

获取原文
获取原文并翻译 | 示例
           

摘要

PurposeTo evaluate the outcomes of fenestrated thoracic endovascular aortic repair (f-TEVAR) using physician-modified stent grafts (PMSGs) in zone 0 and zone 1 for aortic arch diseases.Methodsf-TEVAR using PMSGs in Z0 and Z1 was performed on ten high-risk patients for open surgery from November 2015 to September 2017. Indications were complicated acute type B dissection (ABAD) with retrograde dissection involving the mid-arch (n=1), distal arch aneurysms (n=3), mid-arch aneurysms of the inner arch curvature (n=3) and penetrating aortic ulcer located in the mid- or proximal arch (n=3). Pre-, intra- and postoperative clinical data were recorded.ResultsThe median patient age was 61 (range 45-81) years, and 9 (90%) patients were men. Ten PMSGs (Medtronic Valiant stent grafts, n=1; Relay thoracic stent grafts, n=4; Cook TX2 device, n=5) were deployed. PMSGs were deployed from Z0 and Z1 in 5 and 5 patients, respectively. Double small fenestrations for the left subclavian artery (LSA) and the left common carotid artery (LCCA), respectively, were created in 3 patients. Triple small fenestrations for the innominate artery (IA), the LCCA and the LSA, respectively, were created in 2 patients. One large fenestration for both the IA and the LCCA combined with one small fenestration for the LSA was created in 3 patients. One large fenestration for the LCCA combined with one small fenestration for the LSA was created in 2 patients. Posterior diameter-reducing ties were added to all the devices except to one Valiant stent graft. All but 2 patients underwent elective procedure. Median duration for stent graft modifications was 105 (range 90-125)min. The technical success rate was 90%. Overall mortality was 10% (1/10). One patient died of sudden cardiac arrest intraoperatively after the deployment of the PMSG and all the supra-aortic branch stents. Mean operative time was 106.043.0min, and fluoroscopy time was 30.6 +/- 22.9min. There were no type I or type III endoleaks, perioperative neurological complications or spinal cord ischemia. Median length of stay was 8 (range 4-35) days. Nine patients survived at mean 13.3 (range 6.0-19.0) months follow-up. Retrograde dissection occurred in one patient of Z0 group 40days post-f-TEVAR and resolved after open repair. During follow-up, all target vessels remained patent without fenestration-related type I or III endoleaks.Conclusions f-TEVAR using PMSGs in Z0 and Z1 for the treatment of aortic arch diseases in high-risk patients is feasible in the hands of experienced operators.
机译:Puposeto评估使用的医生改性支架移植物(PMSG)在0和主动脉弓疾病的区域1中使用医生改性支架移植物(PMSG)的近期胸腔血管内主动脉修复(F-Tevar)的结果。在十个高度下使用Z0和Z1中使用PMSGS的PMSGSF-Tevar - 2015年11月至2017年11月开放手术风险患者。适应症是复杂的急性型B分析(ABAD),涉及中拱(n = 1),远端拱形动脉瘤(n = 3),中间拱形动脉瘤(N = 3)的逆行解剖内拱曲率(n = 3)和渗透主动脉溃疡位于中或近拱(n = 3)中。记录前,术后和术后临床数据。患者年龄的中位数患者年龄为61(45-81岁)岁,9例(90%)患者是男性。十个PMSG(Medtronic Valiant支架移植物,n = 1;继电器胸支架移植物,n = 4;康复TX2器件,n = 5)被部署。 PMSG分别从Z0和Z1部署5例和5名患者。左亚克拉夫动脉(LSA)和左侧常见的颈动脉(LCCA)分别在3名患者中分别进行双重衰落。在2名患者中,分别为无名动脉(IA),LCCA和LSA的三倍小衰落。 IA和LCCA的一个大型衰减结合了LSA的一个小衰生,在3名患者中创建。 LCCA的一个大型衰生结合了LSA的一个小兴奋剂,在2名患者中创建。除了一个易型支架移植物之外的所有装置中加入了后径减小的关系。除了2名患者之外的所有选修程序。支架移植修饰的中位持续时间为105(范围90-125)分钟。技术成功率为90%。总体死亡率为10%(1/10)。在展开PMSG和所有上述主动脉支架后,一名患者在术后死于心脏猝灭。平均手术时间为106.043.0分钟,透视时间为30.6 +/- 22.9min。没有I型或III型胚乳,围手术期神经系统并发症或脊髓缺血。中位数逗留时间为8(范围4-35)天。九个患者在平均值13.3(范围为6.0-19.0)个月后存活。逆行解剖发生在Z0组400ds的一名患者在F-Tevar后,并在开放修复后解决。在随访期间,所有目标船只都仍然是没有更新相关的I或III endoleaks的专利。结论F-Tevar在Z0和Z1中使用PMSG,用于治疗高危患者的主动脉弓疾病在经验丰富的运营商手中是可行的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号